Nature Medicine
11, 507 - 514 (2005)
Published online: 17 April 2005; | doi:10.1038/nm1232
PI 3-kinase p110 : a new target for antithrombotic therapyShaun P Jackson, Simone M Schoenwaelder, Isaac Goncalves, Warwick S Nesbitt, Cindy L Yap, Christine E Wright, Vijaya Kenche, Karen E Anderson, Sacha M Dopheide, Yuping Yuan, Sharelle A Sturgeon, Hishani Prabaharan, Philip E Thompson, Gregg D Smith, Peter R Shepherd, Nathalie Daniele, Suhasini Kulkarni, Belinda Abbott, Dilek Saylik, Catherine Jones, Lucy Lu, Simon Giuliano, Sascha C Hughan, James A Angus, Alan D Robertson
& Hatem H SalemSupplementary Fig. 1 (pdf 48K)
Synthesis of TGX-221, a novel inhibitor of PI 3-kinase. Supplementary Fig. 2 (pdf 52K)
Role of PI3K p110 and  in shear-dependent platelet calcium flux in platelets. Supplementary Fig. 3 (pdf 59K)
Role of PI3K p110 in promoting platelet activation in response to physiological agonists Supplementary Fig. 4 (pdf 64K)
Effect of TGX-221 on P2Y1-dependent calcium flux and platelet shape change in ADP-stimulated platelets. Supplementary Fig. 5 (pdf 70K)
Antithrombotic effect of TGX-221. Supplementary Fig. 6 (pdf 41K)
Dration of the antithrombotic effect of TGX-221 following a single i.v. bolus. Supplementary Table 1 (pdf 52K)
Relative inhibitory potency of TGX-221 against a broad panel of lipid and protein kinases. Supplementary Methods (pdf 57K)
|
